These LoIs mark a significant milestone in the Company's product development journey. Following several years of successful preclinical research and development, Eevia is preparing for clinical studies on both products, with the aim of launching them to market in 2026.

MaxBIOME™ and ProRENIS™ target gut health and kidney health, respectively—two high-growth categories in the global nutraceutical industry. The Letters of Intent outline a mutual commitment to evaluate and negotiate potential commercial agreements and go-to-market strategies following the completion of clinical trials.

The counterparties are two established nutraceutical corporations, each part of larger multinational groups with global reach.
 

“The interest expressed by these potential partners is strong and compelling,” says Erik Eide, Commercial Director of Eevia Health. “The Letters of Intent confirm a clear intent to collaborate on go-to-market strategies and further validate the commercial potential of our lead pipeline products as we move toward clinical substantiation of their health benefits.”

The Company views this development as a key step in its strategy to bring science-backed, sustainably produced health products to the global market through strong partnerships.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com  or investor@eeviahealth.com                     

Telephone: +358 400 22 5967                         

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga mushroom, and pine bark, are wild harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.